;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • 2B3-201: Phase I data

    to-BBB technologies B.V., Leiden, the Netherlands Product: 2B3-201 Business: Autoimmune Molecular target: NA Description: Glutathione pegylated liposomal methylprednisolone Indication: Treat multiple sclerosis (MS) …

    Published on 9/29/2014
  • Ampion: Phase I data

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide cleaved from…

    Published on 9/29/2014
  • Ampion: Phase III data

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide cleaved from…

    Published on 9/29/2014
  • Cyramza ramucirumab: Additional Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Cyramza ramucirumab (LY3009806, IMC-1121B) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2) …

    Published on 9/29/2014
  • Dex-IN: Phase IIb discontinued

    Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Product: Dex-IN Business: Neurology Molecular target: Adrenergic receptor alpha 2 (ADRA2) Description: Intranasal formulation of dexmedetomidine, an adrenergic receptor …

    Published on 9/29/2014
  • Egalet-001: Clinical trial data

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Product: Egalet-001 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Abuse-deterrent, extended-release, oral formulation of morphine Indication: …

    Published on 9/29/2014
  • Enclomiphene: Phase III data

    Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Enclomiphene (Androxal) Business: Endocrine/Metabolic Molecular target: Androgen receptor; Estrogen receptor Description: Trans-isomer of clomiphene …

    Published on 9/29/2014
  • Humira adalimumab: Phase III data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Humira adalimumab Business: Dermatology Molecular target: Tumor necrosis factor (TNF) alpha Description: Human mAb against tumor …

    Published on 9/29/2014
  • LPCN 1021: Phase III data

    Lipocine Inc. (NASDAQ:LPCN), Salt Lake City, Utah Product: LPCN 1021 Business: Endocrine/Metabolic Molecular target: NA Description: Oral formulation of testosterone that uses Lipocine's Lip'ral oral delivery technology…

    Published on 9/29/2014
  • MEDI9929: Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI9929, AMG 157 Business: Inflammation Molecular target: Thymic stromal lymphopoietin (TSLP) Description: …

    Published on 9/29/2014
  • Mipsagargin: Interim Phase Ib/II data

    GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Product: Mipsagargin (G-202) Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Prodrug of plant-derived cytotoxin …

    Published on 9/29/2014
  • MNK-155: Additional Phase III data

    Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Product: MNK-155, COV155 Business: Neurology Molecular target: NA Description: Extended-release oral formulation of hydrocodone …

    Published on 9/29/2014
  • Olaparib: Phase Ib data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Olaparib (AZD2281, KU-0059436) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Poly(ADP-ribose) polymerase (PARP) inhibitor …

    Published on 9/29/2014
  • Secukinumab: Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A) Description: Human IgG1 mAb targeting IL-17A Indication: Treat psoriatic…

    Published on 9/29/2014
  • Sodium zirconium cyclosilicate: Phase III data

    ZS Pharma Inc. (NASDAQ:ZSPH), Coppell, Texas Product: Sodium zirconium cyclosilicate (ZS-9) Business: Hematology Molecular target: NA Description: Inorganic crystal form of zirconium silicate designed to trap potassium …

    Published on 9/29/2014
  • TD-4208: Phase IIb data

    Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Product: TD-4208 (formerly GSK1160724) Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled long-acting muscarinic …

    Published on 9/29/2014
  • Tenofovir alafenamide fumarate: Phase III data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine) Business: Infectious …

    Published on 9/29/2014
  • Tenofovir alafenamide fumarate: Phase III data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine) Business: Infectious …

    Published on 9/29/2014
  • Vesneo: Phase III data

    Nicox S.A. (Euronext:COX), Sophia Antipolis, France Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: Vesneo (Latanoprostene bunod) (formerly NCX 116, BOL-303259-X) Business: …

    Published on 9/29/2014
  • Viaskin Peanut: Phase IIb data

    DBV Technologies (Euronext:DBV), Bagneux, France Product: Viaskin Peanut (DBV-712) Business: Inflammation Molecular target: NA Description: Peanut proteins epicutaneously delivered by Viaskin patch technology Indication…

    Published on 9/29/2014
  • Vynfinit vintafolide: Additional Phase IIb data

    Endocyte Inc. (NASDAQ:ECYT), West Lafayette, Ind. Product: Vynfinit vintafolide (MK-8109, EC145) Business: Cancer Molecular target: Folate receptor Description: Folate (vitamin B9) linked to alkaloid chemotherapy agent …

    Published on 9/29/2014
  • GAL-021: Clinical trial data

    Galleon Pharmaceuticals Inc., Horsham, Pa. Product: GAL-021 Business: Pulmonary Molecular target: Potassium channel KCa1.1 (KCNMA1) (SLO) Description: Potassium channel KCa1.1 (KCNMA1; SLO) blocker Indication: Treat …

    Published on 9/22/2014
  • GRC 17536: Phase IIa data

    Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296), Mumbai, India Product: GRC 17536 Business: Neurology Molecular target: Transient receptor potential A1 (TrpA1) Description: Transient receptor potential A1 (…

    Published on 9/22/2014
  • Kuvan sapropterin dihydrochloride: Additional Phase IIIb data

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Kuvan sapropterin dihydrochloride (Biopten) (6R-BH4) …

    Published on 9/22/2014
  • LAPS-GCSF: Phase II data

    Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Product: LAPS-GCSF (SPI-2012) (HM10460A) Business: Hematology Molecular target: Granulocyte …

    Published on 9/22/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993